Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.48 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MYOC | Q99972 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | ACR | P10323 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237695 | 0.99 | KMT2A (0.64) | KMT2APKMHGFACMEN1MAPT | |
| SCHEMBL10956570 | 0.86 | KMT2A (0.56) | KMT2AHGFACMEN1MAPTSMN1; SMN2 | |
| SCHEMBL9474762 | 0.84 | KMT2A (0.72) | KMT2APKMHGFACMEN1MAPT | |
| Hydrochloric Acid SCHEMBL7258086 | 0.83 | KMT2A (0.61) | KMT2AMEN1MAPTRAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL7330789 | 0.82 | ACR (0.59) | KMT2AHGFACMEN1MAPTRAB9A | |
| SCHEMBL11316711 | 0.82 | PARP10 (0.61) | KMT2AHGFACMEN1RAB9ANPC1 | |
| SCHEMBL4951809 | 0.82 | KMT2A (0.84) | KMT2APKMHGFACMAPTRAB9A | |
| SCHEMBL10636579 | 0.82 | KMT2A (0.84) | KMT2APKMHGFACMAPTRAB9A | |
| SCHEMBL18434657 | 0.82 | KMT2A (0.84) | KMT2APKMHGFACMAPTRAB9A | |
| SCHEMBL542043 | 0.82 | KMT2A (0.84) | KMT2APKMHGFACMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119212415-A | Perovskite solar cell and preparation method thereof | 国网甘肃省电力公司电力科学研究院 | 2024-12-27 | — | — | CN | claimed |
| US-9810701-B2 | Analysis of direct factor Xa inhibitors | DOASENSE GMBH (DE) | 2017-11-07 | — | — | US | claimed |
| US-20160011218-A1 | ANALYSIS OF DIRECT FACTOR Xa INHIBITORS | DOASENSE GMBH (DE) | 2016-01-14 | — | — | US | claimed |
| US-20150344935-A1 | ANALYSIS OF DIRECT FACTOR Xa INHIBITORS | DOASENSE GMBH (DE) | 2015-12-03 | — | — | US | claimed |
| US-9133501-B2 | Analysis of direct factor Xa inhibitors | Ruprecht-Karls-Universität Heidelberg (DE) | 2015-09-15 | — | — | US | claimed |
| US-20130302839-A1 | ANALYSIS OF DIRECT FACTOR Xa INHIBITORS | UNIVERSITAT HEIDELBERG (DE) | 2013-11-14 | — | — | US | claimed |
| EP-2643475-A1 | ANALYSIS OF DIRECT FACTOR XA INHIBITORS | Ruprecht-Karls-Universität Heidelberg (DE) | 2013-10-02 | — | — | EP | claimed |
| WO-2012069139-A1 | ANALYSIS OF DIRECT FACTOR XA INHIBITORS | Ruprecht-Karls-Universität Heidelberg (DE) | 2012-05-31 | — | — | WO | claimed |
| US-20250090644-A1 | E. COLI EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | Shenzhen Bay Laboratory (CN) | 2025-03-20 | — | — | US | disclosed |
| EP-4511113-A1 | A SHORT IN VIVO HALF-LIFE AND IN VIVO UNSTABLE RECOMBINANT MICROPLASMIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD OF TREATING THROMBOEMBOLISM RELATED DISEASES INCLUDING ADMINISTRATION THEREOF | Shenzhen Bay Laboratory (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-4496888-A1 | AN E. COLI EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | Shenzhen Bay Laboratory (CN) | 2025-01-29 | — | — | EP | disclosed |
| CN-119212415-A | Perovskite solar cell and preparation method thereof | 国网甘肃省电力公司电力科学研究院 | 2024-12-27 | — | — | CN | disclosed |
| CN-119053700-A | Recombinant human microfibrillatase expressed by escherichia coli, production method thereof, pharmaceutical composition containing recombinant human microfibrillatase and kit, and method for treating thromboembolism-related diseases by using recombinant human microfibrillatase | 深圳湾实验室 | 2024-11-29 | — | — | CN | disclosed |
| US-11964004-B2 | Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof | Shenzhen Bay Laboratory (CN) | 2024-04-23 | — | — | US | disclosed |
| US-4722890-A | SENSITIVE ENZYME LINKED IMMUNOSORBENT ASSAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1988-02-02 | — | — | US | disclosed |
| US-4545988-A | Urokinase-plasmin complex adsorbable by fibrin and process for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-08 | — | — | US | disclosed |
| US-4536391-A | REACTING A PLASMIN HEAVY CHAIN WITH UROKINASE IN THE PRESENCE OF A COUPLING AGENT | OTSUKA PHARMACEUTICAL CO. (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0151308-A2 | Urokinase complex adsorbable by fibrin and process for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-08-14 | — | — | EP | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4056519-A | TRIPEPTIDYL-4-METHOXY-2-NAPHTHYLAMIDE | ELI LILLY AND COMPANY (US) | 1977-11-01 | — | — | US | disclosed |